Partner Therapeutics secured its first FDA approval with Bizengri, a bispecific antibody for advanced cholangiocarcinoma driven by NRG1 gene fusions. The approval adds a new targeted option for a biologically defined subgroup where treatment choices can be limited. Partner previously acquired U.S. rights to the asset from Merus in 2024, positioning the company to commercialize the therapy in the United States after regulatory review. The approval also highlights continued momentum for bispecific antibodies in genomically selected tumors, particularly where single-molecule targeted approaches may not be sufficient.